Budgetary impact analysis of buprenorphine-naloxone combination (suboxone®) in Spain

Health Economics Review

Volumn 2, Issue 1, 2012, Pages 1-9

  Martinez Raga, Jose ^a   Gonzalez Saiz, Francisco ^b   Oñate, Julian ^c   Oyagüez, Itziar ^d   Sabater, Eliazar ^d   Casado, Miguel A ^d  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL DE JEREZ   (Spain)

^c Drogodependencias y Salud Mental   (Spain)

^d Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

Budgetary impact; Buprenorphine naloxone; Methadone; Opioid dependence; Spain

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; METHADONE;

ARTICLE; BUDGET; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE AVAILABILITY; HEALTH CARE DISTRIBUTION; HEALTH CARE UTILIZATION; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OPIATE ADDICTION; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIMULATION; SPAIN;

EID: 84971260484     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-2-3     Document Type: Article

References (51)

1. United Nations Office on Drugs and Crime: UNODC. World Drug Report 2010 (United Nations Publication, Sales No. E.10.XI.13). [http://www. unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res. pdf], (accessed on 2011, June 16).
2. Ministerio de Sanidad, Politica Social e Igualdad: National Program on Drugs (Plan Nacional sobre drogas) Observatorio Español sobre Drogas. Informe 2009. [http://www.pnsd.mspsi.es/Categoria2/observa/pdf/oed-2009. pdf], (accessed on 2011, June 16).
3. Mark TL, Woody GE, Juday T, Kleber HD: The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001, 61:195-206.
4. Hall W, Darke S: Trends in opiate overdose deaths in Australia 1979-1995. Drug Alcohol Depend 1998, 52:71-77.
5. Gonzalez G, Oliveto A, Kosten TR: Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother 2004, 5:713-725.
6. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ: A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010, 30:155-166.
7. Gowing L, Farrell M, Ali R, White JM: Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2009, 2: CD002024.
8. Soyka M, Kranzler HR, van den Brink W, Krystal J, Möller HJ, Kasper S, WFSBP Task Force on Treatment, Guidelines for Substance Use Disorders: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry 2011, 12:160-187.
9. Uchtenhagen A: Substitution management in opioid dependence. J Neural Transm Suppl 2003, 66:33-60.
10. George S, Day E: Buprenorphine in the treatment of opioid dependence. Br J Hosp Med (Lond) 2007, 68:594-597.
11. Maremmani I, Gerra G: Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict 2010, 19:557-568.
12. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S: Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004, 75:37-45.
13. Ling W, Rawson RA, Compton MA: Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs 1994, 26:119-128.
14. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D: Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998, 93:475-486.
15. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE: A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995, 40:17-25.
16. Kakko J, Svanborg KD, Kreek MJ, Heilig M: 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003, 361:662-668.
17. European Medicines Agency: Summary of Products Characteristics (Suboxone).[http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/000697/WC500058505.pdf], (accessed on 2011, June 14).
18. Johnson RE, Strain EC, Amass L: Buprenorphine: how to use it right. Drug Alcohol Depend 2003, 70(2 Suppl):S59-77.
19. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D: Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphinenaloxone. N Engl J Med 2003, 349:949-958.
20. Doran CM: Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2005, 5:583-591.
21. Horspool MJ, Seivewright N, Armitage CJ, Mathers N: Post-treatment outcomes of buprenorphine detoxification in community settings: a systematic review. Eur Addict Res 2008, 14:179-185.
22. Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG: Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study. Clin Drug Investig 2010, 30(Suppl 1):21-26.
23. Niezen MG, de Bont A, Busschbach JJ, Cohen JP, Stolk EA: Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int J Technol Assess Health Care 2009, 25:49-55.
24. Martínez-Raga J, González Saiz F, Pascual C, Casado MA, Sabater Torres FJ: Suboxone (buprenorphine/naloxone) as an agonist opioid treatment in Spain: a budgetary impact analysis. Eur Addict Res 2010, 16:31-42.
25. Brosa M, Gisbert R, Rodríguez JM, Soto J: Principios, métodos y aplicaciones del análisis del impacto presupuestario en el sector sanitario. PharmacoEconomics Span Res Art 2005, 2:64-78.
26. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P: Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 2007, 10:336-347.
27. Orlewska E, Mierzejewski P: Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004, 7:1-10.
28. Trueman P, Drummond M, Hutton J: Developing guidance for budget impact analysis. Pharmacoeconomics 2001, 19:855-867.
29. Lilford R, Royston G: Decision analysis in the selection, design and application of clinical and health services research. J Health Serv Res Policy 1998, 3:159-166.
30. Ministerio de Sanidad, Política Social e Igualdad: National Program on Drugs (Plan Nacional sobre drogas) Memoria 2009. [http://www.pnsd. msc.es/Categoria2/publica/pdf/memo2009.pdf], (accessed on 2011, June 16).
31. Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Anen SJ, Brooks AC, Jiang H, Akerele E, Nunes EV: Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007, 91:289-292.
32. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A: Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011, 4:CD001333.
33. World Health Organization: Collaboration centre for drugs statistics methodology.[http://www.whocc.no/atc_ddd_index/?code=N07BC51], (accessed on 2011, June 13).
34. National Statistics Institute: Instituto Nacional de Estadística. Indice de precios al consumo.[http://www.ine.es/calcula/index.do?L=0], (accessed on 2011, June 14).
35. Royal Decree-Law [Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. BOE de 24 de mayo de 2010:126]. [http://www.boe.es/boe/dias/ 2010/05/24/pdfs/BOE-A-2010-8228.pdf], (accessed on 2011, July 02).
36. IMS Health. MIDAS, MAT. [database]. 2010.
37. Sacristan JA, Galende I, Soto J: Estudios naturalísticos para valorar la efectividad de los medicamentos tras su comercialización: ¿por qué, cuándo y cómo? Aten Primaria 1998, 22:182-185.
38. de Wet CJ, Reed LJ, Bearn J: The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001-03. Addiction 2005, 100:495-499.
39. Raisch DW, Campbell HM, Garnand DA, Jones MA, Sather MR, Naik R, Ling W: Health-related quality of life changes associated with buprenorphine treatment for opioid dependence. Qual Life Res 2011.
40. Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S: Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007, 5:146-150.
41. Ling W, Wesson DR, Charuvastra C, Klett CJ: A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996, 53:401-407.
42. Petitjean S, Stohler R, Déglon JJ, Livoti S, Waldvogel D, Uehlinger C, Ladewig D: Double-blind randomized trial of buprenorphine and methadone in opiatedependence. Drug Alcohol Depend 2001, 62:97-104.
43. Johnson RE, Jaffe JH, Fudala PJ: A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992, 267:2750-2755.
44. Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA: Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med 2011, 5:254-263.
45. Rosenheck R, Kosten T: Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend 2001, 63:253-262.
46. Davids E, Gastpar M: Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 2004, 14:209-216.
47. Barros PP: The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econ 2011, 20:461-470.
48. Espín J, Oliva J, Rodríguez-Barrios JM: Innovative patient access schemes for the adoption of new technology: risk-sharing agreements. Gac Sanit 2010, 24:491-497.
49. de Pouvourville G: Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ 2006, 7:155-157.
50. Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R: Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ Policy Law 2011, 6:391-403.
51. Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuolienè K, Haycox A, Garattini S, Gustafsson LL: Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010, 10:153.